Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Digestive System Neoplasms, Endocrine Gland Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Breast Diseases, Renal Neoplasm, Solid Tumors

In brief

The objectives of this study are to explore different dosing levels and schedules of entinostat in combination with pembrolizumab in patients with advanced solid tumors, in terms of safety, tolerability, pharmacokinetics (PK), impact on immune correlatives, and efficacy

Key facts

Study ID

NCT02909452

Run by

Syndax Pharmaceuticals

People needed

30

Starts

2016-09-20

Expected to finish

2021-02-09

Last updated by the study team

2022-01-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Completed Study SNDX-275-0140 (NCT02897778)
• Any AE or toxicity experienced in Study SNDX-275-0140 (NCT02897778) is resolved to less than or equal to Grade 1
• Continues to meet inclusion criteria for Study SNDX-275-0140 (NCT02897778) at the time of entry into this study

You may not qualify if…

• Completed Study SNDX-275-0140 (NCT02897778) more than 30 days prior to Cycle 1 Day 1 of this study
• Continues to meet exclusion criteria for Study SNDX-275-0140 (NCT02897778) at the time of entry into this study

Where it is running

• The START Center for Cancer Care — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.